Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 6/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.39 |
| ▸ | SQLE | Q14534 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1017016 | 0.87 | TSHR (0.37) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL28342394 | 0.85 | KMT2A (0.70) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL27437786 | 0.85 | KMT2A (0.70) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL22223989 | 0.84 | — | — | |
| SCHEMBL1013293 | 0.84 | — | — | |
| SCHEMBL11708648 | 0.80 | KDM4E (0.42) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL14166465 | 0.77 | ALOX15 (0.35) | ALOX15ALDH1A1TSHRGBA1GBA2 | |
| SCHEMBL59251 | 0.77 | — | — | |
| SCHEMBL1014132 | 0.77 | — | — | |
| SCHEMBL25973601 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108473484-B | Compounds useful as TRPM8 modulators | 弗门尼舍公司 | 2021-06-29 | — | — | CN | disclosed |
| EP-2781522-A1 | OPTICALLY ACTIVE BISOXAZOLINE COMPOUND, ASYMMETRIC CATALYST, AND METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOPROPANE COMPOUND USING SAID CATALYST | Sumitomo Chemical Company, Limited (JP) | 2014-09-24 | — | — | EP | disclosed |
| US-7705165-B2 | Method for producing optically active cyclopropanecarboxylate compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-27 | — | — | US | disclosed |
| US-7671210-B2 | Process for production of optically active cyclopropanecarboxylate compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-03-02 | — | — | US | disclosed |
| US-20090048450-A1 | Process for production of optically active cyclopropanecarboxylate compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048450-A1 | Process for production of optically active cyclopropanecarboxylate compound | CBR3, C9, CBR1 | KMT2A 4416/4885ALOX15 1218/4885MEN1 1576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.